The Neuroendovascular Coil Market was valued at USD 1.04 billion in 2024, and is projected to reach USD 1.52 billion by 2030, rising at a CAGR of 6.50%. This growth is attributed to the increasing incidence of cerebral aneurysms and strokes, fueled by aging populations and lifestyle-related risk factors such as hypertension, smoking, and diabetes.
Technological advancements have significantly enhanced procedural efficacy and safety, including developing next-generation detachable, hydrogel-coated, and 3D complex coils. According to the data by NIH 2025, each year, an estimated 795,000 people in the U.S. experience a stroke, with approximately 610,000 of these being first-time occurrences. Nearly one in four stroke survivors will suffer a subsequent stroke. Among all stroke cases, about 87% are classified as ischemic strokes, while the remaining 13% are hemorrhagic strokes.
The aging population significantly drives the neuroendovascular coil market due to the higher prevalence of neurological conditions, such as aneurysms, which are more common in older adults. As the elderly population grows, the demand for minimally invasive treatments, such as neuroendovascular coil embolization, increases, as these procedures are safer and involve quicker recovery than traditional surgery. Additionally, the higher risk of complications in older patients, such as aneurysms bursting or strokes, further boosts the demand for neuroendovascular coils. Healthcare systems worldwide are adapting to the needs of aging populations, increasing treatment resources, and creating favorable reimbursement policies, which helps expand the market. Moreover, the focus on improving the quality of life for elderly individuals enhances the demand for advanced, minimally invasive options such as neuroendovascular coils, contributing to the market's growth.
The below graph presents projected data on the proportion of the population aged 65 and older across various OECD countries by the year 2050, highlighting the global trend of population aging. Countries such as South Korea (39.8%), Japan (37.7%), and Italy (33.7%) are expected to have the highest percentages of elderly individuals, indicating rapid demographic shifts driven by increased life expectancy and declining birth rates. Additionally, it indicates a growing demand for age-related medical interventions and technologies, such as neuroendovascular coils, as the incidence of conditions such as stroke is expected to rise with the aging demographic.
Hypertension is one of the most significant risk factors for a variety of vascular diseases, including cerebral aneurysms, strokes, and other cerebrovascular abnormalities. Its growing prevalence globally is a critical factor driving the expansion of the neuroendovascular coil market. Neuroendovascular coils are widely used in the treatment of brain aneurysms and vascular malformations, which are caused or exacerbated by uncontrolled hypertension. Hypertension is the leading cause of hemorrhagic strokes. It contributes to the narrowing and hardening of arteries, making them more susceptible to blockage or rupture. Neuroendovascular procedures, including the use of coils, are a frontline treatment for hemorrhagic strokes caused by ruptured aneurysms. The increasing global burden of hypertension, especially in low- and middle-income countries where blood pressure control is insufficient, is expected to lead to a rise in stroke cases, thereby propelling the demand for neuroendovascular interventions. According to the British Heart Foundation BHF, 2025, it is estimated that around 30% of UK adults, approximately 16 million people, are living with high blood pressure, and up to half of them are not receiving effective treatment. While about 11 million individuals have been diagnosed by their general practitioner, this suggests that up to 5 million adults may remain undiagnosed. In total, up to 8 million people in the UK could be living with undiagnosed or uncontrolled high blood pressure.
Aneurysms in the brain, which occur when blood vessels weaken and form a bulge, are a significant concern among the aging population. The risk of aneurysms increases with age, particularly after age 50. As the number of elderly individuals rises globally, the occurrence of aneurysms has become more prevalent, fueling demand for treatment options. Neuroendovascular coils are one of the preferred methods for treating these aneurysms, as they involve less invasive techniques than traditional surgery, making them more suitable for elderly patients who may have other health concerns or are not candidates for more invasive procedures.
This product will be delivered within 1-3 business days.
Technological advancements have significantly enhanced procedural efficacy and safety, including developing next-generation detachable, hydrogel-coated, and 3D complex coils. According to the data by NIH 2025, each year, an estimated 795,000 people in the U.S. experience a stroke, with approximately 610,000 of these being first-time occurrences. Nearly one in four stroke survivors will suffer a subsequent stroke. Among all stroke cases, about 87% are classified as ischemic strokes, while the remaining 13% are hemorrhagic strokes.
The aging population significantly drives the neuroendovascular coil market due to the higher prevalence of neurological conditions, such as aneurysms, which are more common in older adults. As the elderly population grows, the demand for minimally invasive treatments, such as neuroendovascular coil embolization, increases, as these procedures are safer and involve quicker recovery than traditional surgery. Additionally, the higher risk of complications in older patients, such as aneurysms bursting or strokes, further boosts the demand for neuroendovascular coils. Healthcare systems worldwide are adapting to the needs of aging populations, increasing treatment resources, and creating favorable reimbursement policies, which helps expand the market. Moreover, the focus on improving the quality of life for elderly individuals enhances the demand for advanced, minimally invasive options such as neuroendovascular coils, contributing to the market's growth.
The below graph presents projected data on the proportion of the population aged 65 and older across various OECD countries by the year 2050, highlighting the global trend of population aging. Countries such as South Korea (39.8%), Japan (37.7%), and Italy (33.7%) are expected to have the highest percentages of elderly individuals, indicating rapid demographic shifts driven by increased life expectancy and declining birth rates. Additionally, it indicates a growing demand for age-related medical interventions and technologies, such as neuroendovascular coils, as the incidence of conditions such as stroke is expected to rise with the aging demographic.
Hypertension is one of the most significant risk factors for a variety of vascular diseases, including cerebral aneurysms, strokes, and other cerebrovascular abnormalities. Its growing prevalence globally is a critical factor driving the expansion of the neuroendovascular coil market. Neuroendovascular coils are widely used in the treatment of brain aneurysms and vascular malformations, which are caused or exacerbated by uncontrolled hypertension. Hypertension is the leading cause of hemorrhagic strokes. It contributes to the narrowing and hardening of arteries, making them more susceptible to blockage or rupture. Neuroendovascular procedures, including the use of coils, are a frontline treatment for hemorrhagic strokes caused by ruptured aneurysms. The increasing global burden of hypertension, especially in low- and middle-income countries where blood pressure control is insufficient, is expected to lead to a rise in stroke cases, thereby propelling the demand for neuroendovascular interventions. According to the British Heart Foundation BHF, 2025, it is estimated that around 30% of UK adults, approximately 16 million people, are living with high blood pressure, and up to half of them are not receiving effective treatment. While about 11 million individuals have been diagnosed by their general practitioner, this suggests that up to 5 million adults may remain undiagnosed. In total, up to 8 million people in the UK could be living with undiagnosed or uncontrolled high blood pressure.
Aneurysms in the brain, which occur when blood vessels weaken and form a bulge, are a significant concern among the aging population. The risk of aneurysms increases with age, particularly after age 50. As the number of elderly individuals rises globally, the occurrence of aneurysms has become more prevalent, fueling demand for treatment options. Neuroendovascular coils are one of the preferred methods for treating these aneurysms, as they involve less invasive techniques than traditional surgery, making them more suitable for elderly patients who may have other health concerns or are not candidates for more invasive procedures.
Global Neuroendovascular Coil Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the global neuroendovascular coil market report based on type, application, end use, and region:Type Outlook (Revenue, USD Million, 2018-2030)
- Bare Platinum Coils
- Hydrogel-Coated Coils
Application Outlook (Revenue, USD Million, 2018-2030)
- Cerebral Infarction
- Cerebral Aneurysm
- Arteriovenous Malformation (AVM)
- Others
End Use Outlook (Revenue, USD Million, 2018-2030)
- Hospitals
- Ambulatory Surgery Centers
- Specialty Clinics
- Others
Regional Outlook (Revenue, USD Million, 2018-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Neuroendovascular Coil Market Variables, Trends, & Scope
Chapter 4. Neuroendovascular Coil Market: Type Business Analysis
Chapter 5. Neuroendovascular Coil Market: Application Business Analysis
Chapter 6. Neuroendovascular Coil Market: End Use Business Analysis
Chapter 7. Neuroendovascular Coil Market: Regional Estimates & Trend Analysis by Technology and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this Neuroendovascular Coil market report include:- Penumbra, Inc
- Kaneka Medical Europe N.V.
- Stryker
- Lepu Medical Technology (Beijing) Co.,Ltd
- Balt
- NeuroSafe Medical Co., Ltd.
- Johnson & Johnson
- Boston Scientific Corporation
- Medtronic
- Terumo Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.04 Billion |
| Forecasted Market Value ( USD | $ 1.52 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
